ReviewFrontiers in pediatrics2026
Lung function impairment in children post-tuberculosis treatment: a systematic review and meta-analysis.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Hospitalization for tuberculosis in children and adolescents: clinical, epidemiological characteristics and post-treatment sequelae at a referral center in Brazil.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary tuberculosis (PTB) in childhood can result in persistent lung function impairment in adults, but data among children remain limited. This systematic review and meta-analysis aimed to summarize and update current evidence on pulmonary function outcomes after PTB treatment in children. Methods: We searched PubMed, Embase, Web of Science, and Scopus up to October 23, 2025. Eligible studies included children (≤18 years) with PTB who underwent post-treatment spirometry. Pooled mean z-scores for FEV₁, FVC, and FEV1/FVC ratio were calculated using random-effects models. For comparative studies, standardised mean differences (Hedges' g) were derived to compare post-PTB children with healthy controls. Results: Nine studies were included. The pooled post-treatment mean z-scores indicated significant reductions in both FEV₁ (-1.51, 95% CI -2.38 to -0.64) and FVC (-1.36, 95% CI -2.60 to -0.12), while the FEV1/FVC ratio showed no significant deviation (0.04, 95% CI -1.29 to 1.37). In case-control comparisons, post-PTB children had significantly lower FEV₁ (Hedges' g = -0.46, 95% CI -0.78 to -0.13) and FVC (Hedges' g = -0.29, 95% CI -0.50 to -0.08) compared with controls, while the FEV1/FVC ratio (Hedges' g = -0.32, 95% CI -0.58 to -0.06) showed only a marginal decline. Heterogeneity across analyses was moderate to high (I Conclusions: This updated systematic review and meta-analysis indicates that children who have completed PTB treatment frequently exhibit FEV₁ and FVC values below age matched reference levels, although estimates vary substantially across studies. Pooled effect sizes should be interpreted as indicative of association rather than precise estimates of magnitude. Additional prospective, microbiologically confirmed, and age-specific studies are necessary to better understand the long-term effects of childhood TB on lung development. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, PROSPERO CRD420251166413.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.